One study used 3 prostate cancer cell lines (androgen responsive and non-responsive) to develop RR derivates; they identified enhanced EMT/cancer stem cell phenotypes and activation of checkpoint proteins and PI3K/AKT/mTOR signalling pathways in the RR cells [31]. The gene discussed is MTOR; the disease is prostate carcinoma.